341 related articles for article (PubMed ID: 32660118)
1. The Janus Face of p53-Targeting Ubiquitin Ligases.
Hao Q; Chen Y; Zhou X
Cells; 2020 Jul; 9(7):. PubMed ID: 32660118
[TBL] [Abstract][Full Text] [Related]
2. Essential Roles of E3 Ubiquitin Ligases in p53 Regulation.
Sane S; Rezvani K
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218667
[TBL] [Abstract][Full Text] [Related]
3. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
Satija YK; Bhardwaj A; Das S
Int J Cancer; 2013 Dec; 133(12):2759-68. PubMed ID: 23436247
[TBL] [Abstract][Full Text] [Related]
4. Targeting Chemoresistant Tumors: Could TRIM Proteins-p53 Axis Be a Possible Answer?
Valletti A; Marzano F; Pesole G; Sbisà E; Tullo A
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30974870
[TBL] [Abstract][Full Text] [Related]
5. Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers.
Martinho MS; Nancarrow DJ; Lawrence TS; Beer DG; Ray D
Cell Mol Gastroenterol Hepatol; 2021; 11(2):449-464. PubMed ID: 33130332
[TBL] [Abstract][Full Text] [Related]
6. The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest.
Corcoran CA; Huang Y; Sheikh MS
Cancer Biol Ther; 2004 Aug; 3(8):721-5. PubMed ID: 15280670
[TBL] [Abstract][Full Text] [Related]
7. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.
Liu J; Zhang C; Wang XL; Ly P; Belyi V; Xu-Monette ZY; Young KH; Hu W; Feng Z
Cell Death Differ; 2014 Nov; 21(11):1792-804. PubMed ID: 25146927
[TBL] [Abstract][Full Text] [Related]
8. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
[TBL] [Abstract][Full Text] [Related]
9. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
Takayama KI; Suzuki T; Tanaka T; Fujimura T; Takahashi S; Urano T; Ikeda K; Inoue S
Oncogene; 2018 Apr; 37(16):2165-2180. PubMed ID: 29379164
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
Yang L; Song T; Cheng Q; Chen L; Chen J
Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
[TBL] [Abstract][Full Text] [Related]
11. TRIM proteins and diseases.
Watanabe M; Hatakeyama S
J Biochem; 2017 Feb; 161(2):135-144. PubMed ID: 28069866
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway.
Bang S; Kaur S; Kurokawa M
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905981
[TBL] [Abstract][Full Text] [Related]
13. Making sense of ubiquitin ligases that regulate p53.
Jain AK; Barton MC
Cancer Biol Ther; 2010 Oct; 10(7):665-72. PubMed ID: 20930521
[TBL] [Abstract][Full Text] [Related]
14. The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines.
Ka WH; Cho SK; Chun BN; Byun SY; Ahn JC
Breast Cancer; 2018 Sep; 25(5):529-538. PubMed ID: 29516369
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.
Allende-Vega N; Saville MK
Semin Cancer Biol; 2010 Feb; 20(1):29-39. PubMed ID: 19897040
[TBL] [Abstract][Full Text] [Related]
16. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53.
Chen Y; Hao Q; Wang J; Li J; Huang C; Zhang Y; Wu X; Lu H; Zhou X
Cell Death Dis; 2019 Sep; 10(10):737. PubMed ID: 31570706
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease.
Gorniak P; Budziszewska B; Pula B; Wasylecka M; Borg K; Nowak G; Makuch-Lasica H; Lech-Maranda E; Warzocha K; Juszczynski P
Leuk Lymphoma; 2016; 57(6):1471-3. PubMed ID: 26414098
[No Abstract] [Full Text] [Related]
19. Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system.
Shkedy D; Gonen H; Bercovich B; Ciechanover A
FEBS Lett; 1994 Jul; 348(2):126-30. PubMed ID: 8034027
[TBL] [Abstract][Full Text] [Related]
20. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
Daks AA; Melino D; Barlev NA
Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
